Compare CBNK & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBNK | ADCT |
|---|---|---|
| Founded | 1974 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 519.9M | 431.2M |
| IPO Year | 2018 | 2019 |
| Metric | CBNK | ADCT |
|---|---|---|
| Price | $33.70 | $1.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $35.50 | $7.75 |
| AVG Volume (30 Days) | 55.4K | ★ 2.7M |
| Earning Date | 04-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ 60.85 | 30.86 |
| EPS | ★ 0.73 | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | $16.20 | N/A |
| Revenue Next Year | $8.52 | $66.49 |
| P/E Ratio | $45.90 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $26.40 | $0.78 |
| 52 Week High | $36.40 | $4.98 |
| Indicator | CBNK | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 68.12 | 15.96 |
| Support Level | $30.00 | N/A |
| Resistance Level | $35.00 | $4.77 |
| Average True Range (ATR) | 0.87 | 0.18 |
| MACD | 0.21 | -0.22 |
| Stochastic Oscillator | 92.69 | 10.44 |
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage. The company generates majority revenue from the Commercial bank sector. Commercial Banking division focuses on providing personalized service to commercial clients throughout the operations supplemented by lending outside primary market as well as engaging in government guaranteed lending on a national basis.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).